We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-15.44%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$155M
AUM Growth
-$168M
Cap. Flow
-$112M
Cap. Flow %
-72.13%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$3.46M

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$80M
2
GILD icon
Gilead Sciences
GILD
+$24.2M
3
CYTK icon
Cytokinetics
CYTK
+$10.7M
4
VOR icon
Vor Biopharma
VOR
+$132K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
1
Innoviva
INVA
$1.55B
$51.1M 33%
2,816,022
-4,460,978
-61% -$80M
NBIX icon
2
Neurocrine Biosciences
NBIX
$16.8B
$34.2M 22.1%
309,116
– –
CYTK icon
3
Cytokinetics
CYTK
$10.5B
$24.1M 15.59%
600,000
-233,799
-28% -$10.7M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$696M
$24.1M 15.57%
16,390,000
– –
AMRN
5
Amarin Corp
AMRN
$299M
$11.1M 7.2%
1,242,531
– –
LNTH icon
6
Lantheus
LNTH
$6.49B
$9.76M 6.31%
100,000
+37,000
+59% +$3.46M
VOR icon
7
Vor Biopharma
VOR
$1.15B
$365K 0.24%
25,401
-5,499
-18% -$132K
GILD icon
8
Gilead Sciences
GILD
$162B
– –
-262,080
Closed -$24.2M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Sarissa Capital Management held 8 positions worth $155M, down 52% from $323M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management withdrew a net $112M in Q1 2025, closing 1 position and reducing 3 holdings. Its most notable exit was Gilead Sciences, an estimated $24.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sarissa Capital Management added an estimated $3.46M to Lantheus.

  • Sarissa Capital Management added most to Lantheus in Q1 2025, an estimated $3.46M increase.
  • Sarissa Capital Management's biggest Q1 2025 reduction was Innoviva, cutting an estimated $80M.
  • Sarissa Capital Management fully exited Gilead Sciences in Q1 2025, selling an estimated $24.2M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $155M portfolio in Q1 2025.
  • Sarissa Capital Management opened 0 new positions and closed 1 in Q1 2025.
  • Sarissa Capital Management's portfolio value fell 52% quarter-over-quarter to $155M.

Based on Sarissa Capital Management's 13F filing for Q1 2025, filed 15 May 2025.